<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00899795</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00001025</org_study_id>
    <secondary_id>P30CA069533</secondary_id>
    <secondary_id>OHSU-HEM-02008-LX</secondary_id>
    <secondary_id>CDR0000445436</secondary_id>
    <nct_id>NCT00899795</nct_id>
  </id_info>
  <brief_title>Evaluating Cell Damage in Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, or Fanconi Anemia; in Patients Who Were Exposed to Alkylating Agents; and in Healthy Volunteers</brief_title>
  <official_title>Stromal Injury and Clonal Adaptation in Myelodysplasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OHSU Knight Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>OHSU Knight Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Studying samples of bone marrow from patients with cancer and from healthy&#xD;
      volunteers in the laboratory may help doctors learn more about changes that occur in bone&#xD;
      marrow stromal (connective tissue) cells. It may also help doctors understand the effects of&#xD;
      alkylating agents on bone marrow stromal cells.&#xD;
&#xD;
      PURPOSE: This laboratory study is evaluating stromal cells in patients with acute myeloid&#xD;
      leukemia, myelodysplastic syndromes, or Fanconi anemia; in patients who were exposed to&#xD;
      alkylating agents; and in healthy volunteers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine abnormal stromal function in patients with acute myeloid leukemia (AML),&#xD;
           myelodysplastic syndromes (MDS), or Fanconi anemia; in patients who were exposed to&#xD;
           alkylating agents; and in healthy volunteers.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine whether clonal progenitors from patients with secondary AML or MDS are&#xD;
           resistant to selected extracellular apoptotic cues.&#xD;
&#xD;
        -  Determine whether stromal function in patients with secondary AML or MDS is more&#xD;
           aberrant than stromal function in patients with primary AML or MDS.&#xD;
&#xD;
        -  Determine whether cytotoxic agents known to induce secondary MDS or AML influence the&#xD;
           supportive function of the bone marrow stroma.&#xD;
&#xD;
        -  Determine whether cytoprotective agents reduce both cytotoxicity and genotoxicity in&#xD;
           hematopoietic progenitor cells and stromal cells.&#xD;
&#xD;
      OUTLINE: Patients and healthy volunteers undergo bone marrow sample collection. Progenitor&#xD;
      cells are grown in culture. Cell survival is quantified by flow cytometric and cytogenetic&#xD;
      analysis, sister chromatid exchange, and FISH for chromosome 11 changes (for&#xD;
      etoposide-exposed samples only).&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 24 patients and healthy volunteers will be accrued for this&#xD;
      study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2002</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Abnormal stromal function</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clonal progenitors resistant to selected extracellular apoptotic cells</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of stromal function between secondary vs primary acute myeloid leukemia or myelodysplastic syndromes</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influence of cytotoxic agents on supportive function of the bone marrow stroma</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of cytotoxicity and genotoxicity in hematopoietic progenitor cells and stromal cells with use of cytoprotective agents</measure>
  </secondary_outcome>
  <enrollment type="Actual">35</enrollment>
  <condition>Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>cytogenetic analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>fluorescence in situ hybridization</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>flow cytometry</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>biopsy</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Inpatient, outpatient, and normal volunteers&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Meets 1 of the following criteria:&#xD;
&#xD;
               -  Diagnosis of acute myeloid leukemia or myelodysplastic syndromes and requires&#xD;
                  bone marrow aspiration/biopsy for clinical purposes&#xD;
&#xD;
                    -  Primary or secondary disease&#xD;
&#xD;
               -  Diagnosis of Fanconi anemia by positive mitomycin C test (age 5 to 55 years)&#xD;
&#xD;
               -  Received prior chemotherapy containing any of the following alkylating agents:&#xD;
                  mechlorethamine, chlorambucil, cyclophosphamide, melphalan, busulfan, or&#xD;
                  topoisomerase inhibitors&#xD;
&#xD;
               -  Healthy volunteer (age 18 and over), meeting the following criteria:&#xD;
&#xD;
                    -  CBC normal&#xD;
&#xD;
                    -  WBC &gt; 1,000/mm³&#xD;
&#xD;
                    -  Hemoglobin &gt; 10 g/dL&#xD;
&#xD;
                    -  Platelet count &gt; 70,000/mm³&#xD;
&#xD;
          -  No bone marrow metastases&#xD;
&#xD;
          -  No evidence of non-hematopoietic malignancy&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  No clinical signs and symptoms of acute or subacute infection (viral, bacterial, or&#xD;
             fungal infection)&#xD;
&#xD;
          -  No allergy to lidocaine or xylocaine&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 6 months since prior cytotoxic or immunosuppressive agents&#xD;
&#xD;
          -  No prior extensive pelvic radiotherapy (&gt; 20 Gy)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Grover C. Bagby, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>OHSU Knight Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>OHSU Knight Cancer Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239-3098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <study_first_submitted>May 9, 2009</study_first_submitted>
  <study_first_submitted_qc>May 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2009</study_first_posted>
  <last_update_submitted>November 30, 2017</last_update_submitted>
  <last_update_submitted_qc>November 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>OHSU Knight Cancer Institute</investigator_affiliation>
    <investigator_full_name>Grover Bagby</investigator_full_name>
    <investigator_title>Professor Emeritus</investigator_title>
  </responsible_party>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(15;17)(q22;q12)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <keyword>untreated adult acute myeloid leukemia</keyword>
  <keyword>childhood myelodysplastic syndromes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

